

Conference on ‘Over- and undernutrition: challenges and approaches’

Symposium 2: Modern approaches to nutritional research challenges Targeted and non-targeted approaches for metabolite profiling in nutritional research

John K. Lodge

Cranfield Health, Vincent Building, Cranfield University, Cranfield, Bedfordshire MK43 0AL, UK

The present report discusses targeted and non-targeted approaches to monitor single nutrients and global metabolite profiles in nutritional research. Non-targeted approaches such as metabolomics allow for the global description of metabolites in a biological sample and combine an analytical platform with multivariate data analysis to visualise patterns between sample groups. In nutritional research metabolomics has generated much interest as it has the potential to identify changes to metabolic pathways induced by diet or single nutrients, to explore relationships between diet and disease and to discover biomarkers of diet and disease. Although still in its infancy, a number of studies applying this technology have been performed; for example, the first study in 2003 investigated isoflavone metabolism in females, while the most recent study has demonstrated changes to various metabolic pathways during a glucose tolerance test. As a relatively new technology metabolomics is faced with a number of limitations and challenges including the standardisation of study design and methodology and the need for careful consideration of data analysis, interpretation and identification. Targeted approaches are used to monitor single or multiple nutrient and/or metabolite status to obtain information on concentration, absorption, distribution, metabolism and elimination. Such applications are currently widespread in nutritional research and one example, using stable isotopes to monitor nutrient status, is discussed in more detail. These applications represent innovative approaches in nutritional research to investigate the role of both single nutrients and diet in health and disease.

Metabolomics: Metabolite profiling: Stable isotopes: Nutrient physiology: Diet

Nutritional change is accepted as a cornerstone of public health strategy in reducing the risk of many of the chronic diseases that face Western society such as obesity, heart disease and cancer. Nutritional status modulates virtually all body processes, including various ongoing metabolic processes⁽¹⁾. Currently, however, there is little understanding of the individual response to nutritional intervention and the contribution that specific metabolites and metabolic pathways make in physiological processes related to health and disease⁽²⁾. In trying to elucidate the aetiology of multifactorial disease it is well accepted that genetic, environmental and lifestyle factors are important modulators. Nutrition also plays an important role as it supplies the metabolome (all metabolites within a biological

sample). During disease development early events lead to a change to nutrient physiology and/or changes to metabolic pathways, which will influence the whole metabolome and may eventually lead to a metabolic disturbance and the origins of a disease phenotype. Using traditional biomarkers and conventional research tools it is not possible to identify changes to nutrients and the metabolome at these early stages when nutritional intervention could potentially reduce disease risk back to a healthy phenotype. However, there are now a number of approaches available to monitor both single-nutrient physiology and global metabolite profiles, and these approaches have shown considerable potential in the study of how diet and the metabolome interact. Such approaches can be defined

Abbreviation: LC, liquid chromatography.

Corresponding author: Dr John K. Lodge, fax +44 1234 758380, email j.k.lodge@cranfield.ac.uk

as either targeted or non-targeted depending on the overall experimental design. Targeted approaches are usually hypothesis testing, as it presumes the target of the investigation is known (nutrient or metabolite) and the aim of the study is to measure its status. A non-targeted approach is usually hypothesis generating, as typically it is designed to provide a more global description of all metabolites present in a biological fluid; thus, the target is actually the whole metabolome and not a specific species. The aim then is to identify species of interest that can be targeted for further investigation and as such both approaches are linked and complementary to each other.

Non-targeted approaches: metabolomics

Metabolomics is a relatively novel technology in nutritional research and offers considerable potential as a result of the wealth of information that potentially can be obtained. There is increasing interest in the use of metabolomics as a tool in understanding the effects of nutritional intervention on the individual^(1,3–10). A major challenge is to understand the relationship between nutrition and chronic disease, and a metabolomics-based approach could be used analytically to predict susceptibility to metabolic diseases and elucidate molecular mechanisms that can explain the beneficial effects of dietary interventions. Furthermore, metabolomics is thought to be a promising tool for biomarker discovery⁽²⁾, with the potential capacity to identify biomarkers of early-stage disease and biomarkers of dietary patterns or individual nutrients. Metabolomics is also seen as providing critical information in the quest to transform current population-based dietary guidelines into future personalised dietary recommendations to help individuals maintain a healthier status and prevent chronic diseases⁽¹¹⁾.

The technology can be summarised as a global analysis or characterisation of all metabolites measured in a biological sample (metabolome). The metabolome is a complex mixture of thousands of compounds that arise from intra- and extracellular metabolic pathways and external sources such as food. As a result of the complexity of biological fluids, with the large number of metabolites present, data from biological mixtures are highly complex and generally are processed using multivariate statistical analysis including pattern recognition. These chemometric measurements generate metabolic profiles or patterns of metabolites from which it is then possible to detect changes to the normal phenotype induced by, for example in relation to nutritional studies, diet and metabolic disease. Although this technology has been successfully used in nutritional studies, there are still a number of considerations for its use.

Methodological considerations for metabolomic investigations

Metabolomics requires an analytical platform to supply the metabolite profiles before subsequent data processing. A number of technology platforms are available to analyse biological samples but NMR and MS are the commonest and each has its own advantages and disadvantages.

Historically, NMR has been the platform of choice and still represents the most common method for sample analysis in metabolomics. More recently, MS technology has become popular, with both liquid chromatography (LC) and GC being successfully used. NMR requires no sample pretreatment and so the spectrum contains information on both small-molecular-weight compounds and proteins; however, sensitivity is relatively low. MS is highly sensitive; however, it requires sample pretreatment in the removal of proteins and hydrophobic compounds, thus limiting potential information. Furthermore, the method of protein precipitation or sample treatment also has its own analytical considerations and influences the metabolite profiles obtained. As pretreatment and a separation step are needed, MS is not as reproducible as NMR. A general consideration for metabolomic investigations is that no single platform will provide information on all metabolites present and a combination of NMR, LC–MS and GC–MS would be required.

Experimental and analytical variation

Analytical design and variation in relation to metabolomics has been extensively investigated^(12–20). As each platform has its own analytical requirements, variation arises from the methodology used in the study and from the instrument itself. Sample collection provides its own issues. Although blood concentrations of metabolites are generally under some sort of metabolic regulation, they are dynamic and responsive to acute changes to the diet. Metabolite profiles have been shown to be influenced by the blood collection tubes⁽²¹⁾, clotting times and clotting procedure⁽¹⁵⁾. Urine represents an ‘end point’ of metabolism, and as such is not under any metabolic regulatory control as with plasma or serum, and is often the sample of choice in metabolomics investigations (it also requires limited pretreatment compared with blood). However, urinary metabolite profiles are heavily influenced by diurnal variation⁽¹²⁾ and the use of sample preservatives⁽²²⁾, especially if 24 h aliquots are being obtained. The extent to which spot urines or first or second void urines are representative has not yet been established. The use of faeces (either lyophilised or faecal water) is relatively new but can be useful for gut microflora investigations. Sample storage is important; no differences have been found in urinary or plasma metabolite profiles when samples are stored for 0 or 24 h at 4°C⁽²³⁾, but for longer storage times sub-zero conditions (<–20°C) should be used^(14,22). Freeze–thaw cycles have not been shown to influence metabolite profiles using LC–MS⁽¹⁴⁾.

While NMR requires no sample pretreatment, MS requires removal of proteins and hydrophobic lipids. Various methods for protein precipitation have been compared in terms of the number of features obtained^(13,24,25), with similar observations finding methanol treatment to be the most optimal for plasma samples; however, the variation in profiles obtained from each pretreatment method is extensive. Attempts have been made to further develop and optimise the methodology for LC–MS-based metabolomic studies^(13,16,17,20,26). It is clear that the analytical conditions associated with MS need to be further optimised and standardised as sample pretreatment, run time, type of

column, temperature and LC gradient all influence the profiles obtained^(13,16,17,20,26).

Biological variation

There is a complex relationship between genotype, metabolic phenotype, diet, lifestyle and environment and the nutritional needs of an individual⁽¹¹⁾. Human tissues and cells respond to the delivery of nutrients by adapting their metabolic processes through the regulation of gene transcription, protein levels and enzyme activity. The end point of these processes is that the levels of metabolites change; however, as a result of large inter-individual variations in genotype and phenotype human subjects differ widely in their response to nutrients and diet overall⁽¹¹⁾ and thus there is large inter-individual variability in metabolite profiles.

The influence of biological variation has been the subject of some study^(18,19,27,28). Considerable biological variation in metabolite profiles exists as a result of gender, age and BMI^(27,28) and it has been possible to classify samples based on these characteristics. Increased plasma choline, LDL, HDL and unsaturated fatty acids have been found in women and increased VLDL, creatine and isoleucine in men as discriminators of gender⁽²⁷⁾. Comparing age-groups, in women plasma valine, isoleucine, alanine and tyrosine are higher in the older population (>46 years v. 18–29 years) while in men plasma lipoproteins and unsaturated lipids are higher in the older population⁽²⁷⁾. Discriminators based on BMI include choline and citrate, which are higher in a lean population (BMI<21 kg/m²), while tyrosine, isoleucine and glycoproteins are higher in an obese population (BMI>25 kg/m²)⁽²⁷⁾. Thus, in terms of study design there needs to be a careful consideration of the population used, with limited ranges of age and BMI and also taking into account blood pressure⁽²⁹⁾, standard clinical chemistry and prescreening questionnaires⁽¹⁰⁾.

Dietary habits heavily influence metabolite profiles, as foods contain thousands of compounds that supply the metabolome. Populations can be classified according to various dietary factors^(29–31) and certain metabolites have been shown to be related to specific dietary patterns^(30,32,33). For example, trimethylamine N-oxide is related to acute intake of fish^(30,31) while taurine and creatine are increased during high meat intakes^(30,32). Careful dietary standardisation is therefore required before sample collection^(10,34), and indeed this approach has been shown to decrease inter-individual variation in urinary metabolite profiles⁽³⁴⁾.

There is a complex interaction between gut microflora and host metabolism^(35,36). As diet modulates microbial physiology, products of microbial metabolism can enter the host metabolome causing substantial variability in profiles. Although urinary metabolite profiles have often been used as a natural point to observe such interactions⁽³⁷⁾, recent evidence suggests that there is a large contribution of microbial by-products to the plasma metabolome⁽³⁶⁾. A comparison of conventional (with microflora) and germ-free (without microflora) mice has found numerous signals exclusive to the presence of microflora, with approximately a 10% difference in the metabolite profiles between

normal and germ-free animals⁽³⁶⁾. As well as products of microbial metabolism of amino acids and other compounds, the study has also found products of host phase II metabolism raised in the presence of microflora, demonstrating a direct effect on host drug metabolism capacity⁽³⁶⁾. Faeces are an obvious sample to study microflora interactions, as profiles contain a plethora of compounds related to microflora metabolism such as SCFA, organic acids and amino acid derivatives⁽³⁸⁾. As the complement of microflora differs between individuals there is considerable inter- and intra-individual variation in profiles⁽³⁸⁾, but interestingly this variation has been found to be a result of differences in concentration rather than composition⁽³⁸⁾. Nevertheless, as microflora seem to contribute to both blood and urinary profiles they are an important contributor to biological variation.

Data analysis

The data produced by metabolomics experiments are highly complex; for example, >2000 features differing in intensity by orders of magnitude are typically represented in LC–MS analysis of plasma or urine. As the technology aims to characterise changes to the metabolome in discreet sets of samples powerful multivariate statistical analysis techniques are required to process the data for sample classification and clustering or discrimination. These techniques essentially are data compression tools; by reducing the dimensionality of the data it becomes easier to visualise graphically so that patterns between groups of data (samples) can be revealed. Both unsupervised and supervised techniques are commonly used. Principal component analysis is an unsupervised method for sample classification. The ‘principal components’ represent variance between samples and so samples that are similar in their metabolite profile will cluster together in a scores plot. An important aspect of this method is that it does not require information about sample classification and as such is a good starting point to visualise the data. However, principal component analysis is often unable to classify similar groups, which is typically found in nutritional studies, and so other techniques are often used. Supervised methods, such as partial least squares discriminant analysis, include information on sample classification, making it more likely that patterns of change between groups are visualised. However, the downside is that it can lead to overanalysis, e.g. partial least squares discriminant analysis will separate groups from random data⁽³⁹⁾, and as such these methods require appropriate model validation steps and adequate training and predictive sample sets, usually with independent data.

Clustering methods, as described earlier, only visualise discriminated sample groups demonstrating whether the metabolite profiles are different between sample groups. This feature is important to establish, but of greater interest is identifying what metabolites are responsible for the variation between sample groups, as this information can be used further downstream in pathway analysis and biomarker identification. Loadings plots are an extension to score plots in which those features responsible for group variation are visualised. Although this approach provides

Table 1. A summary of human nutritional metabolomic studies

Reference	Platform	Study	Sample
Solanky <i>et al.</i> ^(42,43)	NMR	Isoflavone (soyabean) intake in healthy females: daily controlled intake either normal or rich in soya, 1 month per treatment (<i>n</i> 5; females)	Plasma ⁽⁴²⁾ , urine ⁽⁴³⁾
Lenz <i>et al.</i> ⁽³⁰⁾	NMR	Population comparisons, dietary influences: no intervention, compared healthy British v. Swedish subjects (<i>n</i> 30; mixed)	Urine
Daykin <i>et al.</i> ⁽⁴⁴⁾	NMR	Black tea metabolism: single dose of black tea following a low-polyphenol diet (<i>n</i> 3; mixed)	Urine
Wang <i>et al.</i> ⁽⁴⁶⁾	NMR	Chamomile-tea metabolism: 2 weeks control, then 2 weeks of tea every day, then 2 weeks no tea; spot urines taken every day (<i>n</i> 14; mixed)	Urine
Van Dorsten <i>et al.</i> ⁽⁴⁵⁾	NMR	Comparison of green tea, black tea and caffeine: cross-over design; 2 d run-in of low-polyphenol diet followed by 2 d treatment, 10 d washout (<i>n</i> 17; males)	Urine, plasma
Walsh <i>et al.</i> ⁽³⁴⁾	NMR	Dietary standardization: no intervention, three visits the latter two following same dietary pattern (<i>n</i> 30; mixed)	Urine, plasma, saliva
Stella <i>et al.</i> ⁽³²⁾	NMR	Comparison of a vegetarian v. low-meat v. high-meat diets: randomised cross-over design; 15 d treatment periods (<i>n</i> 12; men)	Urine
Walsh <i>et al.</i> ⁽⁴⁷⁾	NMR and LC-MS	Acute phytochemical intake: 6 d study, day 0 normal, days 1 and 2 low-phytochemical diet, days 3 and 4 addition of fruit and vegetables (<i>n</i> 21; mixed)	Urine
Rezzi <i>et al.</i> ⁽³³⁾	NMR	Dietary preferences; chocolate intake: subjects defined by chocolate desiring or not; 5 d study, days 2 and 4 subjects given chocolate or bread in cross-over design with washout days between (eleven men in each group)	Plasma
Kemsley <i>et al.</i> ⁽⁷⁷⁾	NMR	Cu intervention: case study, three experimental phases with urine collections; 1st phase only collection, 2nd phase included dietary records, 3rd phase collections followed 6 weeks of Cu supplement (<i>n</i> 6; men)	Urine
von Velzen <i>et al.</i> ⁽⁴⁹⁾	NMR	Wine polyphenols: double-blind controlled cross-over design, 2-week run-in followed by 4 weeks of placebo and mix of wine and grape juice extract (<i>n</i> 29; mixed)	Urine
Grün <i>et al.</i> ⁽⁴⁸⁾	GC-MS	Microbial fermentation of polyphenol-rich extract and green tea: used samples from study of von Velzen <i>et al.</i> ⁽⁴⁹⁾ ; stool samples taken for 3 d following eight cups green tea (<i>n</i> 26, mixed plasma and urine; <i>n</i> 1, faeces)	Plasma, urine, faeces
Jacobs <i>et al.</i> ⁽³⁸⁾	NMR	Microbial fermentation following grape juice, wine extract: double-blind controlled cross-over design, 2-week run-in followed by 4 weeks of placebo, grape juice extract and mix of wine and grape juice extract (<i>n</i> 53; mixed)	Faeces
Shaham <i>et al.</i> ⁽⁵⁰⁾	LC-MS	Targeted metabolite profiling following glucose challenge: analysis of a mixed young (<i>n</i> 22; mixed) and older (<i>n</i> 25; mixed) population, both undergoing an oral glucose tolerance test; targeted analysis of 191 metabolites	Plasma
Chorell <i>et al.</i> ⁽⁵²⁾	GC-MS	Exercise and influence of different CHO drinks: cross-over design, single dose; 90 min exercise followed by either water, low-CHO drink, high-CHO drink or low-CHO and protein drink, 1-week washout (<i>n</i> 24; men)	Serum
Zhao <i>et al.</i> ⁽⁵¹⁾	LC-MS	Changes to metabolome following oral glucose tolerance test: samples from subjects undergoing an oral glucose tolerance test (<i>n</i> 16; not specified)	Plasma

LC, liquid chromatography; CHO, carbohydrate.

important information on the actual species (e.g. mass and retention time in LC-MS experiments), further investigative work using metabolite databases (e.g. the human metabolome database⁽⁴⁰⁾, METLIN⁽⁴¹⁾) and confirmatory analysis using standards is required to be fully confident of the assignment.

It should be noted that data analysis steps require careful consideration and interpretation in order to be confident of obtaining meaningful data.

Metabolomics in nutritional research

A number of studies applying metabolomics to nutritional research have been performed (Table 1). A quick comparison of these studies shows that various analytical platforms and biological samples have been used. Generally, NMR has been the most common platform but MS has been gaining popularity over recent years, perhaps because of greater availability and improvement in

analytical technology and methodology. Urine is still the commonest biological sample used, especially when NMR is used as the platform, but a number of studies do profile both urine and blood. It is interesting to note that the first 'real' nutritional metabolomics study was performed in 2003⁽⁴²⁾, which highlights the novelty of the technology. These early studies have shown changes to both the plasma⁽⁴²⁾ and later the urinary⁽⁴³⁾ metabolome following ingestion of isoflavones (soyabean) in healthy premenopausal women. In plasma there are changes to lipoproteins, amino acids and carbohydrates following intervention⁽⁴²⁾ while in urine there are changes associated with modification of gut microflora⁽⁴³⁾. Importantly, the 'urine' study used controlled environmental conditions with standardised meals, which perhaps contributed to identifying subtle changes to the metabolome in a relatively small subject population (five females). A number of studies of differing design have been performed on tea metabolism⁽⁴⁴⁻⁴⁶⁾. While both black tea and chamomile tea

confirm hippuric acid as a major species responsible for variation^(44,45), green tea produces additional effects on metabolites involved in the citric acid cycle⁽⁴⁶⁾. The first study to compare diets (vegetarian v. low meat v. high meat) in a cross-over design (twelve men) has found certain metabolites characteristic of high meat (creatine, acyl and free carnitine, trimethylamine N-oxide) and vegetarian (*p*-hydroxyphenylacetate) diets⁽³²⁾. A comparison of normal, low-phytochemical and standardised-phytochemical diets in twenty-one individuals (mixed gender) has found increased hippuric acid excretion during the standard-phytochemical diet and increased creatinine and methyl histidine excretion during the low-phytochemical diet⁽⁴⁷⁾. Interestingly, direct comparison of NMR and LC-MS shows a similar classification of diets between the platforms⁽⁴⁷⁾. An interesting study that has examined dietary preferences has found a difference in the urinary and plasma metabolite profile of subjects classified as either 'chocolate desiring' or 'chocolate indifferent' even before any food intake, suggesting that dietary preference alone influences metabolic rate and gut flora activity⁽³³⁾. A number of studies have investigated microbial fermentation of polyphenol-rich extracts such as grape juice or wine extract and again have found the presence of hippuric acid and its derivatives as well as phenolic acids as major contributors to sample classification^(38,48,49). Interestingly, the use of faeces as a sample has demonstrated changes to gut-flora fermentation induced by a wine extract⁽³⁸⁾. More recently, metabolomic studies have investigated carbohydrate intake either during an oral glucose tolerance test^(50,51) or following consumption of energy drinks⁽⁵²⁾. The former studies have identified various pathways stimulated during the insulin response to glucose, some of which have not previously been reported^(50,51).

Metabolomics has been used to investigate the influence of vitamin E supplementation (400 mg/d, 4 weeks) on plasma metabolite profiles of twelve healthy men using LC-MS (JK Lodge and MC Wong, unpublished results). While principal component analysis has failed to demonstrate discrimination of samples, a validated partial least squares discriminant analysis model has been able to discriminate samples pre- and post supplementation. Further investigation of loadings plots has revealed several features for further investigation that have been confirmed to be significantly different pre- and post supplementation ($P < 0.05$). Preliminary identification of these features has revealed a number of lysophospholipids that are significantly increased following vitamin E supplementation ($P < 0.05$). Although the confirmation of these species is still ongoing, this finding highlights the potential of the technology in being able to identify changes to the metabolome and the identification of novel areas of research that may go unnoticed using conventional techniques.

Future perspectives for nutritional metabolomics

Although the potential of metabolomics is without question, the technology is still faced with a number of limitations and challenges. There is no single platform that can analyse all metabolites in a biological sample and so the limitations of each technology have to be taken into

account in experimental design. Obviously, a combination of NMR, LC-MS and GC-MS would be ideal to provide a more holistic measure of the metabolome, but this approach itself brings important cost implications and an increase in data analysis and complexity. There is currently no standardisation in terms of the methodology associated with sample collection, sample pretreatment and analytical conditions. However, there have been recommendations published to standardise metabolomic investigations and their reporting^(53,54), which will hopefully influence future investigations. A major challenge is the influence of both analytical and biological variability. Analytical variability should improve with the advancement of technology and standardisation of methodology, while the influence of biological variability requires careful understanding of the influence of a variety of factors such as gender, BMI, age, recent dietary intake, gut microflora and general health, as these factors have all been shown to influence the metabolome. Furthermore, the influence of lifestyle, genetic and environmental factors, which are important in the aetiology of chronic disease, need to be further explored. Such considerations have implications for study design to create a relatively homogenous study population to reduce the influence of biological variation.

Another major challenge faced is the identification of metabolites. Although a number of databases are available for most platforms (and should be used in conjunction with each other), as the whole metabolome is not yet fully characterised there will always be a problem with the identification of 'unknowns'. Although useful structural information can be gained from further MS experiments (e.g. fragmentation), identification ultimately requires the use of standards, and if not commercially available the assistance of synthetic chemists.

The future potential of this technology for nutritional research can be envisaged at various levels. It will be possible to integrate metabolomics with other 'omic' technologies to provide a more complete picture of the metabolic phenotype. The identification of those metabolites influenced by certain nutrients and/or dietary patterns can be useful for predictive analysis with the possibility of using fluxomics (dynamic changes of metabolites within a cell over time) to investigate the flow of metabolites through metabolic pathways, especially now, as human metabolic networks have been constructed⁽⁵⁵⁾. A well-established role for nutritional metabolomics has been identified in the development of the nutritional phenotype and for future personalised nutritional assessment^(1,3,4,9). It is thought that metabolomics can be used to predict the response of the metabolome to nutrient or dietary intervention and to predict dietary change required to modify the metabolome to a 'healthy' phenotype. Although personalised nutrition is a long way off, metabolomics does offer the possibility of characterising the complex interactions between diet and the metabolome.

Targeted approaches

Targeted approaches are more hypothesis testing and include those in which the nutrient(s) or metabolite(s) of interest are known and information on concentration,

bioavailability, turnover or metabolism are required. These approaches can also be seen as a natural progression from non-targeted approaches that are used in the first instance to identify novel targets for such further studies. Targeted analysis can cover either single nutrients or metabolites or an analysis of metabolome subsets including lipids⁽⁵⁶⁾, amino acids⁽⁵⁷⁾ and central metabolism⁽⁵⁰⁾. Indeed, the profiling of lipids has developed into its own field of lipidomics and recent studies in this field, which include the analysis of eicosanoid metabolism and signalling⁽⁵⁸⁾, identifying lipids linked to inflammation following fish oil intervention⁽⁵⁹⁾, phospholipid metabolism⁽⁶⁰⁾, monitoring of lipid fluxes using stable isotopes⁽⁶¹⁾ and evaluating differential effects of statins⁽⁶²⁾, demonstrate how this particular field is rapidly progressing.

Simply measuring concentration alone provides only limited information; therefore, in order to gain further understanding of the physiology of a nutrient or metabolite other approaches are required. A commonly-used method is to employ a stable-isotope analogue of the target, which as it should behave identically to the parent compound allows the monitoring of that specific form in the body following ingestion, providing information on absorption, bioavailability, distribution, turnover, metabolism and elimination^(63,64). The use of stable isotopes in nutritional research is extensive and a review of potential applications is beyond the scope of the present report, but there are several reviews that provide a starting point^(64–67).

As an example of the benefits of using stable isotopes this approach has been employed to monitor vitamin E status in various populations using ²H-labelled α -tocopheryl acetate⁽⁶⁸⁾. Vitamin E transport and delivery within the body is governed by the kinetics of plasma lipoprotein metabolism and much of what is now known about vitamin E transport and distribution has been elucidated using stable-isotope approaches. Intestinal absorption requires the presence of adequate fat, and significant differences have been demonstrated in the plasma uptake of labelled α -tocopherol between meals containing 2.7 g fat and 17.5 g fat ($P < 0.001$)⁽⁶⁹⁾. It has been shown that during the absorptive phase there is no discrimination between vitamin E forms⁽⁷⁰⁾, but a number of biokinetic studies have demonstrated the preferential secretion of α -tocopherol in VLDL over other vitamin E forms⁽⁷⁰⁾, so that there is a retention of α -tocopherol in the body⁽⁷¹⁾. The monitoring of labelled α -tocopherol in lipoproteins demonstrates that α -tocopherol transport is dependent on lipoprotein kinetics⁽⁷²⁾, with peaks in α -tocopherol concentration coinciding with lipoprotein dynamics. Overall, following plasma uptake of newly-absorbed α -tocopherol there is a simultaneous decrease in pre-existing or endogenous α -tocopherol concentration. This rapid turnover of α -tocopherol in the plasma such that the 'new' constantly replaces the 'old' is an established phenomenon identified by stable-isotope techniques^(72,73) and also occurs within individual lipoproteins⁽⁷²⁾. A similar phenomenon has been found in blood components, with different patterns of uptake in erythrocytes, platelets and lymphocytes⁽⁷²⁾ representative of simple diffusion or a more-regulated receptor-mediated uptake. Following an understanding of nutrient physiology in a healthy population a comparison can be made with

high-risk populations to provide clues as to how nutrient physiology is influenced. Using stable isotopes differences have been found in α -tocopherol biokinetics between individuals who are normolipidaemic and hyperlipidaemic⁽⁷⁴⁾, between smokers and non-smokers⁽⁷⁵⁾ and between individuals with the apoE3/3 and apoE3/4 alleles⁽⁷⁶⁾. Overall, these studies highlight that vitamin E homeostasis is ultimately dependent on a combination of factors that control its absorption, transport, distribution and metabolism and that, translated to the field of nutritional research, approaches using stable-isotopes are essential to monitor nutrient status *in vivo* and their role in the aetiology of disease.

Conclusions

With the combined array of targeted and non-targeted approaches it is now possible to not only identify metabolites and nutrients that are influenced by dietary change but to also gain a greater understanding of nutrient and metabolite physiology. Both approaches have proved successful in a number of applications and used either alone or in conjunction with one another they represent powerful research methods with the potential of opening novel areas of nutritional research and understanding the role of diet in health and disease.

Acknowledgements

The author wishes to thank the British Heart Foundation, BASF AG and the University of Surrey Pump Priming for funding parts of this work. The author declares no conflict of interest.

References

1. Zeisel SH, Freake HC, Bauman DE *et al.* (2005) The nutritional phenotype in the age of metabolomics. *J Nutr* **135**, 1613–1616.
2. Kussmann M, Raymond F & Affolter M (2006) OMICS-driven biomarker discovery in nutrition and health. *J Biotechnol* **124**, 758–787.
3. German JB, Bauman DE, Burrin DG *et al.* (2004) Metabolomics in the opening decade of the 21st century: building the roads to individualized health. *J Nutr* **134**, 2729–2732.
4. German JB, Roberts MA, Fay L *et al.* (2002) Metabolomics and individual metabolic assessment: the next great challenge for nutrition. *J Nutr* **132**, 2486–2487.
5. Watkins SM & German JB (2002) Toward the implementation of metabolomic assessments of human health and nutrition. *Curr Opin Biotechnol* **13**, 512–516.
6. Gibney MJ, Walsh M, Brennan L *et al.* (2005) Metabolomics in human nutrition: opportunities and challenges. *Am J Clin Nutr* **82**, 497–503.
7. German JB, Watkins SM & Fay LB (2005) Metabolomics in practice: emerging knowledge to guide future dietetic advice toward individualized health. *J Am Diet Assoc* **105**, 1425–1432.
8. Whitfield PD, German AJ & Noble PJ (2004) Metabolomics: an emerging post-genomic tool for nutrition. *Br J Nutr* **92**, 549–555.

9. German JB, Roberts MA & Watkins SM (2003) Personal metabolomics as a next generation nutritional assessment. *J Nutr* **133**, 4260–4266.
10. Rezzi S, Ramadan Z, Fay LB *et al.* (2007) Nutritional metabonomics: applications and perspectives. *J Proteome Res* **6**, 513–525.
11. Go VL, Nguyen CT, Harris DM *et al.* (2005) Nutrient-gene interaction: metabolic genotype-phenotype relationship. *J Nutr* **135**, 3016S–3020S.
12. Maher AD, Zirah SF, Holmes E *et al.* (2007) Experimental and analytical variation in human urine in 1H NMR spectroscopy-based metabolic phenotyping studies. *Anal Chem* **79**, 5204–5211.
13. Bruce SJ, Jonsson P, Antti H *et al.* (2008) Evaluation of a protocol for metabolic profiling studies on human blood plasma by combined ultra-performance liquid chromatography/mass spectrometry: From extraction to data analysis. *Anal Biochem* **372**, 237–249.
14. Gika HG, Theodoridis GA, Wingate JE *et al.* (2007) Within-day reproducibility of an HPLC-MS-based method for metabonomic analysis: application to human urine. *J Proteome Res* **6**, 3291–3303.
15. Teahan O, Gamble S, Holmes E *et al.* (2006) Impact of analytical bias in metabonomic studies of human blood serum and plasma. *Anal Chem* **78**, 4307–4318.
16. Bruce SJ, Tavazzi I, Parisod V *et al.* (2009) Investigation of human blood plasma sample preparation for performing metabolomics using ultrahigh performance liquid chromatography/mass spectrometry. *Anal Chem* **81**, 3285–3296.
17. Guy PA, Tavazzi I, Bruce SJ *et al.* (2008) Global metabolic profiling analysis on human urine by UPLC-TOFMS: issues and method validation in nutritional metabolomics. *J Chromatogr B Analyt Technol Biomed Life Sci* **871**, 253–260.
18. Shurubor YI, Matson WR, Willett WC *et al.* (2007) Biological variability dominates and influences analytical variance in HPLC-ECD studies of the human plasma metabolome. *BMC Clin Pathol* **7**, 9.
19. Sangster TP, Wingate JE, Burton L *et al.* (2007) Investigation of analytical variation in metabonomic analysis using liquid chromatography/mass spectrometry. *Rapid Commun Mass Spectrom* **21**, 2965–2970.
20. Zelena E, Dunn WB, Broadhurst D *et al.* (2009) Development of a robust and repeatable UPLC-MS method for the long-term metabolomic study of human serum. *Anal Chem* **81**, 1357–1364.
21. Drake SK, Bowen RA, Remaley AT *et al.* (2004) Potential interferences from blood collection tubes in mass spectrometric analyses of serum polypeptides. *Clin Chem* **50**, 2398–2401.
22. Lauridsen M, Hansen SH, Jaroszewski JW *et al.* (2007) Human urine as test material in 1H NMR-based metabonomics: recommendations for sample preparation and storage. *Anal Chem* **79**, 1181–1186.
23. Dunn WB, Broadhurst D, Ellis DI *et al.* (2008) A GC-TOF-MS study of the stability of serum and urine metabolomes during the UK Biobank sample collection and preparation protocols. *Int J Epidemiol* **37**, Suppl. 1, i23–i30.
24. Want EJ, O'Maille G, Smith CA *et al.* (2006) Solvent-dependent metabolite distribution, clustering, and protein extraction for serum profiling with mass spectrometry. *Anal Chem* **78**, 743–752.
25. Jiye A, Trygg J, Gullberg J *et al.* (2005) Extraction and GC/MS analysis of the human blood plasma metabolome. *Anal Chem* **77**, 8086–8094.
26. Wong MC, Lee WT, Wong JS *et al.* (2008) An approach towards method development for untargeted urinary metabolite profiling in metabonomic research using UPLC/QTOF MS. *J Chromatogr B Analyt Technol Biomed Life Sci* **871**, 341–348.
27. Kochhar S, Jacobs DM, Ramadan Z *et al.* (2006) Probing gender-specific metabolism differences in humans by nuclear magnetic resonance-based metabonomics. *Anal Biochem* **352**, 274–281.
28. Slupsky CM, Rankin KN, Wagner J *et al.* (2007) Investigations of the effects of gender, diurnal variation, and age in human urinary metabolomic profiles. *Anal Chem* **79**, 6995–7004.
29. Holmes E, Loo RL, Stamlor J *et al.* (2008) Human metabolic phenotype diversity and its association with diet and blood pressure. *Nature* **453**, 396–400.
30. Lenz EM, Bright J, Wilson ID *et al.* (2004) Metabonomics, dietary influences and cultural differences: a 1H NMR-based study of urine samples obtained from healthy British and Swedish subjects. *J Pharm Biomed Anal* **36**, 841–849.
31. Dumas ME, Maibaum EC, Teague C *et al.* (2006) Assessment of analytical reproducibility of 1H NMR spectroscopy based metabonomics for large-scale epidemiological research: the INTERMAP Study. *Anal Chem* **78**, 2199–2208.
32. Stella C, Beckwith-Hall B, Cloarec O *et al.* (2006) Susceptibility of human metabolic phenotypes to dietary modulation. *J Proteome Res* **5**, 2780–2788.
33. Rezzi S, Ramadan Z, Martin FP *et al.* (2007) Human metabolic phenotypes link directly to specific dietary preferences in healthy individuals. *J Proteome Res* **6**, 4469–4477.
34. Walsh MC, Brennan L, Malthouse JP *et al.* (2006) Effect of acute dietary standardization on the urinary, plasma, and salivary metabolomic profiles of healthy humans. *Am J Clin Nutr* **84**, 531–539.
35. Nicholson JK, Holmes E, Lindon JC *et al.* (2004) The challenges of modeling mammalian biocomplexity. *Nat Biotechnol* **22**, 1268–1274.
36. Wikoff WR, Anfora AT, Liu J *et al.* (2009) Metabolomics analysis reveals large effects of gut microflora on mammalian blood metabolites. *Proc Natl Acad Sci USA* **106**, 3698–3703.
37. Nicholls AW, Mortishire-Smith RJ & Nicholson JK (2003) NMR spectroscopic-based metabonomic studies of urinary metabolite variation in acclimatizing germ-free rats. *Chem Res Toxicol* **16**, 1395–1404.
38. Jacobs DM, Deltimple N, van Velzen E *et al.* (2008) (1)H NMR metabolite profiling of feces as a tool to assess the impact of nutrition on the human microbiome. *NMR Biomed* **21**, 615–626.
39. Westerhuis JA, Hoefsloot HCJ, Smit S *et al.* (2008) Assessment of PLS-DA cross validation. *Metabolomics* **4**, 81–89.
40. Wishart DS, Tzur D, Knox C *et al.* (2007) HMDB: the Human Metabolome Database. *Nucleic Acids Res* **35**, D521–D526.
41. Smith CA, O'Maille G, Want EJ *et al.* (2005) METLIN: a metabolite mass spectral database. *Ther Drug Monit* **27**, 747–751.
42. Solanky KS, Bailey NJ, Beckwith-Hall BM *et al.* (2003) Application of biofluid 1H nuclear magnetic resonance-based metabonomic techniques for the analysis of the biochemical effects of dietary isoflavones on human plasma profile. *Anal Biochem* **323**, 197–204.
43. Solanky KS, Bailey NJ, Beckwith-Hall BM *et al.* (2005) Biofluid 1H NMR-based metabonomic techniques in nutrition research – metabolic effects of dietary isoflavones in humans. *J Nutr Biochem* **16**, 236–244.
44. Daykin CA, Van Duynhoven JP, Groenewegen A *et al.* (2005) Nuclear magnetic resonance spectroscopic based studies of the metabolism of black tea polyphenols in humans. *J Agric Food Chem* **53**, 1428–1434.

45. Van Dorsten FA, Daykin CA, Mulder TP *et al.* (2006) Metabonomics approach to determine metabolic differences between green tea and black tea consumption. *J Agric Food Chem* **54**, 6929–6938.
46. Wang Y, Tang H, Nicholson JK *et al.* (2005) A metabonomic strategy for the detection of the metabolic effects of chamomile (*Matricaria recutita* L.) ingestion. *J Agric Food Chem* **53**, 191–196.
47. Walsh MC, Brennan L, Pujos-Guillot E *et al.* (2007) Influence of acute phytochemical intake on human urinary metabolomic profiles. *Am J Clin Nutr* **86**, 1687–1693.
48. Grun CH, van Dorsten FA, Jacobs DM *et al.* (2008) GC-MS methods for metabolic profiling of microbial fermentation products of dietary polyphenols in human and *in vitro* intervention studies. *J Chromatogr B Analyt Technol Biomed Life Sci* **871**, 212–219.
49. van Velzen EJ, Westerhuis JA, van Duynhoven JP *et al.* (2008) Multilevel data analysis of a crossover designed human nutritional intervention study. *J Proteome Res* **7**, 4483–4491.
50. Shaham O, Wei R, Wang TJ *et al.* (2008) Metabolic profiling of the human response to a glucose challenge reveals distinct axes of insulin sensitivity. *Mol Syst Biol* **4**, 214.
51. Zhao X, Peter A, Fritsche J *et al.* (2009) Changes of the plasma metabolome during an oral glucose tolerance test: is there more than glucose to look at? *Am J Physiol Endocrinol Metab* **296**, E384–E393.
52. Choresell E, Moritz T, Branth S *et al.* (2009) Predictive metabolomics evaluation of nutrition-modulated metabolic stress responses in human blood serum during the early recovery phase of strenuous physical exercise. *J Proteome Res* **8**, 2966–2977.
53. Members MSIB, Sansone SA, Fan T *et al.* (2007) The metabolomics standards initiative. *Nat Biotechnol* **25**, 846–848.
54. Griffin JL, Nicholls AW, Daykin CA *et al.* (2007) Standard reporting requirements for biological samples in metabolomics experiments: mammalian/*in vivo* experiments. *Metabolomics* **3**, 179–188.
55. Duarte NC, Becker SA, Jamshidi N *et al.* (2007) Global reconstruction of the human metabolic network based on genomic and bibliomic data. *Proc Natl Acad Sci USA* **104**, 1777–1782.
56. German JB, Gillies LA, Smilowitz JT *et al.* (2007) Lipidomics and lipid profiling in metabolomics. *Curr Opin Lipidol* **18**, 66–71.
57. Noguchi Y, Zhang QW, Sugimoto T *et al.* (2006) Network analysis of plasma and tissue amino acids and the generation of an amino index for potential diagnostic use. *Am J Clin Nutr* **83**, 513S–519S.
58. Gupta S, Maurya MR, Stephens DL *et al.* (2009) An integrated model of eicosanoid metabolism and signaling based on lipidomics flux analysis. *Biophys J* **96**, 4542–4551.
59. Lankinen M, Schwab U, Erkkila A *et al.* (2009) Fatty fish intake decreases lipids related to inflammation and insulin signaling – a lipidomics approach. *PLoS ONE* **4**, e5258.
60. Wang C, Yang J & Nie J (2009) Plasma phospholipid metabolic profiling and biomarkers of rats following radiation exposure based on liquid chromatography-mass spectrometry technique. *Biomed Chromatogr* (Epublication ahead of print version; doi: 10.1002/bmc.1226).
61. Postle AD & Hunt AN (2009) Dynamic lipidomics with stable isotope labelling. *J Chromatogr B Analyt Technol Biomed Life Sci* **877**, 2716–2721.
62. Bergheanu SC, Reijmers T, Zwinderman AH *et al.* (2008) Lipidomic approach to evaluate rosuvastatin and atorvastatin at various dosages: investigating differential effects among statins. *Curr Med Res Opin* **24**, 2477–2487.
63. Bequette BJ, Sunny NE, El-Kadi SW *et al.* (2006) Application of stable isotopes and mass isotopomer distribution analysis to the study of intermediary metabolism of nutrients. *J Anim Sci* **84**, Suppl., E50–E59.
64. Rennie MJ (1999) An introduction to the use of tracers in nutrition and metabolism. *Proc Nutr Soc* **58**, 935–944.
65. Bluck LJ (2009) Recent progress in stable isotope methods for assessing vitamin metabolism. *Curr Opin Clin Nutr Metab Care* **12**, 495–500.
66. Schoeller DA (2003) 2001 uses of stable isotopes in the assessment of nutrient status and metabolism. *Forum Nutr* **56**, 310–311.
67. Turnlund JR (2006) Mineral bioavailability and metabolism determined by using stable isotope tracers. *J Anim Sci* **84**, Suppl., E73–E78.
68. Hall WL, Jeanes YM, Pugh J *et al.* (2003) Development of a liquid chromatographic time-of-flight mass spectrometric method for the determination of unlabelled and deuterium-labelled alpha-tocopherol in blood components. *Rapid Commun Mass Spectrom* **17**, 2797–2803.
69. Jeanes YM, Hall WL, Ellard S *et al.* (2004) The absorption of vitamin E is influenced by the amount of fat in a meal and the food matrix. *Br J Nutr* **92**, 575–579.
70. Traber MG, Burton GW, Ingold KU *et al.* (1990) RRR- and SRR- α -tocopherols are secreted without discrimination in human chylomicrons, but RRR- α -tocopherol is preferentially secreted in very low density lipoproteins. *J Lipid Res* **31**, 675–685.
71. Leonard SW, Paterson E, Atkinson JK *et al.* (2005) Studies in humans using deuterium-labeled alpha- and gamma-tocopherols demonstrate faster plasma gamma-tocopherol disappearance and greater gamma-metabolite production. *Free Radic Biol Med* **38**, 857–866.
72. Jeanes YM, Hall WL & Lodge JK (2005) Comparative ^2H -labelled α -tocopherol biokinetics in plasma, lipoproteins, erythrocytes, platelets and lymphocytes in normolipidaemic males. *Br J Nutr* **94**, 92–99.
73. Traber MG, Rader D, Acuff RV *et al.* (1998) Vitamin E dose-response studies in humans with use of deuterated RRR-alpha-tocopherol. *Am J Clin Nutr* **68**, 847–853.
74. Hall WL, Jeanes YM & Lodge JK (2005) Hyperlipidemic subjects have reduced uptake of newly absorbed vitamin E into their plasma lipoproteins, erythrocytes, platelets, and lymphocytes, as studied by deuterium-labeled α -tocopherol biokinetics. *J Nutr* **135**, 58–63.
75. Proteggente AR, Rota C, Majewicz J *et al.* (2006) Cigarette smokers differ in their handling of natural (RRR) and synthetic (all rac) alpha-tocopherol: a biokinetic study in apoE4 male subjects. *Free Radic Biol Med* **40**, 2080–2091.
76. Lodge JK, Hall WL, Jeanes YM *et al.* (2004) Physiological factors influencing vitamin E biokinetics. *Ann N Y Acad Sci* **1031**, 60–73.
77. Kemsley EK, Le Gall G, Dainty JR *et al.* (2007) Multivariate techniques and their application in nutrition: a metabolomics case study. *Br J Nutr* **98**, 1–14.